AmacaThera announced today that it completed an oversubscribed $10.3 million Series A financing round. Lumira Ventures led the Series A funding, with existing investors Viva BioInnovator and Sprout BioVentures contributing as well. New investors BDC Capital Women in Technology Venture Fund, Inveready, MBX Capital, CR Capital Management, StandUp Ventures and MaRS IAF participated, too, according […]
Pain Management
Dyve Biosciences appoints Camilla V. Simpson to its board
Clinical-stage biotechnology company Dyve Biosciences announced this week that Camilla V. Simpson joined its board of directors. Simpson possesses over 25 years of experience in the biotech industry, currently serving as an independent member of the board of directors at Spruce Biosciences and as a member of the scientific advisory board at Aristea Therapeutics, according […]
Medtronic launches data management software program for Synchromed II
Medtronic (NYSE:MDT) this week launched a cloud-based data management software platform for its Synchromed II drug delivery system. The Efficio platform is designed to allow clinicians to manage targeted drug delivery pump practices to treat patients who have chronic pain, cancer pain and severe spasticity. It consolidates, organizes and provides visual summaries of patient data received […]
Indiana man may proceed with pain pump lawsuit against Medtronic
An Indiana federal judge on Friday dismissed two parts of a lawsuit against Medtronic (NYSE:MDT), but said that the plaintiff can continue to pursue the third count. Kirk Bledsoe sued Medtronic in Indiana state court in 2017 after the company’s Synchromed II pain pump, which Bledsoe had implanted in 2011, failed on two occasions and […]
Pixarbio CEO Reynolds convicted in $13m investor fraud case
Pixarbio founder & CEO Frank Reynolds reportedly faces two decades behind bars after a jury yesterday convicted him of defrauding investors of nearly $13 million. Federal authorities arrested Reynolds, longtime friend and Pixarbio employee Jay Herod and PixarBio CIO Kenneth Stromsland in April 2018 on securities fraud charges, claiming they misled investors about the opioid substitute […]
Satsuma Pharmaceuticals registers $75m IPO
Satsuma Pharmaceuticals has registered an initial public offering, seeking to raise $75 million, according to a regulatory filing. The South San Francisco-based company is working on STS101, a nasal powder version of dihydroergotamine for migraine. It intends to use the money to fund its Phase 3 safety and efficacy clinical trials for STS101, manufacturing costs, […]
Flowonix warns on software anomaly with Prometra pump
Flowonix earlier this month warned about a software anomaly with its Prometra infusion pump that could unexpectedly shut down the device. The Budd Lake, N.J.-based company won FDA approval in February for updated software included in the Prometra system, which is indicated for intrathecal infusion of drug therapy, including infumorph, saline and baclofen. Flowonix warned […]
Ocular Therapeutix’s ophthalmic device gains Medicare coverage early
Ocular Therapeutix (NSDQ:OCUL) said today that the Centers for Medicare and Medicaid Services has assigned a specific and permanent reimbursement J-code for its Dextenza ophthalmic insert, which is approved for the treatment of ocular inflammation and pain following ophthalmic surgery. The code assigned to Dextenza through the Healthcare Common Procedure Coding System will become effective […]
Lyndra to develop ultra-long-acting opioid use disorder therapy
Lyndra Therapeutics (Watertown, Mass.) announced that it is developing an ultra-long-acting oral treatment for opioid use disorder. On average, about 130 Americans die every day from an opioid overdose, according to the Centers for Disease Control and Prevention. Lyndra Therapeutics received a grant from the National Institutes of Health to help find new treatment strategies […]
Medtronic touts new targeted drug delivery study results
Targeted drug delivery and conventional medical management have shown to have a reduction in healthcare use and costs for cancer patients in comparison to conventional medical management alone, according to a new study from Medtronic. The study found that there were significant cost savings to payers and fewer inpatient visits with shorter inpatient stays. It […]
